VC-backed ProNAi Therapeutics increases IPO target to $138 mln
Canadian clinical-stage oncology specialist ProNAi Therapeutics Inc has announced the pricing of its initial public offering of common shares on the NASDAQ Global Market. The company, which expects to begin trading under the symbol "DNAI" this week, is seeking US$138 million in proceeds, which is up from its previously-disclosed target. Founded in 2004, ProNAi is focused on developing a new class of therapies through its DNA interference platform for patients with cancer and hematological diseases. In 2014, the Vancouver-based company raised US$59.5 million in Series D financing from mostly U.S. venture capital firms, including Vivo Capital, Frazier Healthcare Ventures and OrbiMed Advisors.
17 July 2015•2 mins read
